New Zealand-based Pacific Pharmaceuticals says it is cutting 170 jobs, and closing its manufacturing arm, due to what it described as "economic reasons." The firm, which is wholly owned by Holland's Merck Generics group, says it has not made any decisions regarding a new manufacturing location.
The Auckland-headquartered company says it will retain 30 members of staff in its administration, logistics and storage departments, and added that it had established contract mechanisms to ensure continued product supply.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze